Weight Loss in Elderly Patients With Atrial Fibrillation (LOSE-AF): A Randomised Controlled Trial
Weight Loss in Elderly Patients With Atrial Fibrillation (LOSE-AF): A Randomised Controlled Trial
Background Atrial fibrillation (AF) affects over 1 million individuals in the UK and results in costs of over £450 million per year to the National Health Service (NHS). Current rhythm control strategies are limited by high recurrences of AF. New strategies tackling more upstream pathophysiological mechanisms are most needed. The incidence and prevalence of AF markedly increase with age, whilst obesity is the strongest modifiable risk factor for AF. Preliminary data in relatively young patients suggest that weight loss programmes may reduce AF burden and improve AF-related symptoms. Such programmes could be a widely-applicable and cost-effective option in AF management if they are also effective in elderly patients with AF, particularly if they also improve physical performance.
Aim The aim of this study is to investigate whether, in older overweight/obese AF patients, referral to a dietary weight loss programme and behavioral support programme can reduce AF-related symptoms compared to usual care.
Study design Parallel-group, open-label, multi-centre randomised controlled trial. Elderly individuals (60-85 years) with persistent AF and elevated body mass index (BMI; ≥ 27 kg/m2) will be recruited. Participants will be randomly allocated (1:1) to (a) referral to a dietary weight loss and behavioral support programme (intervention) or (b) usual care (control) for 32-to-36 weeks. The primary endpoint is AF-related symptoms determined using the AF Severity Scale (AFSS) Symptoms Severity score. Participants randomised to the study intervention will be referred to a commercial provider (CP) providing the intervention. The primary endpoint will be analysed irrespective of compliance during the scheduled treatment period following an intention-to-treat principle.
Atrial fibrillation (AF) is the most common sustained arrhythmia, and is associated with a two-fold increase in the risk of premature death. Morbidity and mortality related to stroke, heart failure, myocardial infarction, and reduced quality of life, are all common in patients with AF. AF therefore represents a burgeoning public health problem, affecting over 1 million patients in the UK and resulting in estimated costs of over £450 million per annum. The main drivers of AF-related costs are hospitalizations (over £270 million for admissions annually) and outpatient encounters (approximately £50 million for General Practitioner consultations and £36 million for specialist clinic referrals annually)11. Recurrence of AF remains a clinical challenge despite pharmacological and interventional rhythm control strategies. Moreover, currently available therapies have not been consistently shown to reduce AF recurrence and the risk of major adverse events, or to improve long-term prognosis.
The incidence and prevalence of AF are closely linked to increasing age and excess weight. On one hand, advanced age is the most important non-modifiable risk factor for AF and the corollary is that AF is associated with frailty and impaired physical function. Meanwhile, excess weight is of particular interest as results from four large community-based European studies clearly demonstrated that elevated body mass index (BMI) is the strongest modifiable risk factor for incident AF. A large-scale observational cohort study reported a 4% increase in AF-risk per 1-unit increase in body mass index (BMI) after adjustment for cardiovascular risk factors and interim myocardial infarction or heart failure. Moreover, a recent Mendelian randomization study confirmed a causal relationship between increased BMI and incident AF. The precise mechanisms by which obesity increases the risk of development and maintenance of AF are incompletely understood; potential contributors include left atrial (LA) enlargement, left ventricular (LV) hypertrophy, diastolic dysfunction, altered cardiac energetics, and inflammatory/oxidative signalling from the epicardial adipose tissue.
Very low calorie diets, providing less than 800 kcal/d have been used for many years as highly effective methods for inducing weight loss, leading to consistent reductions in visceral fat and overall adiposity. A systematic review showed weight loss at 1 year of 8-14 kg, which was 4.3 kg (95% CI: 1.1 kg, 7.4 kg) greater than the comparator interventions. The historical limitation of very low calorie diets has historically been long-term effectiveness, and there has been growing interest in the use of total meal replacement sachets as part of a wider behavioural programme. This includes individualised one-to-one counselling to motivate and encourage adherence to the diet, as well as support to establish a healthy eating plan when individuals reintroduce food. Results from DiRECT (a cluster-randomised trial assessing a meal replacement programme in patients with type II diabetes) were published recently in The Lancet: the intervention arm reached an average weight loss of 10 kg at 1 year with 45% of individuals achieving complete remission of type II diabetes, which is also a relevant risk factor for AF. Preliminary data suggest that such a programme proved highly effective in reducing AF symptoms in a relatively young group of AF patients where the diet resulted in significant weight loss (>10kg) sustained to 15 months. However, it remains unclear whether the beneficial effects of weight loss translate in (a) reducing AF recurrences and (b) whether they also extend to the more typical elderly patient population with AF, as reversing cardiac remodelling may prove more difficult in aged hearts. Additionally, the balance between beneficial and detrimental effects of weight loss in the elderly may be dependent on preservation of muscle strength.
The aim of this study is to investigate whether, in older overweight/obese AF patients, referral to a dietary weight loss and behavioral support programme can reduce AF-related symptoms compared to usual care.
This is a parallel-group, open-label, randomized controlled study. The expected duration of the trial intervention is approximately 8 months, with a total of two study visits (at baseline and at 8 months). AF-related symptoms (primary endpoint) are assessed at baseline and at approximately 8 months after the commencement of the intervention using the AFSS symptom score.
Elderly individuals (60-85 years) with elevated BMI (≥27 kg/m2), who are scheduled for a DCCV with a diagnosis of persistent AF will be recruited. Participants will be randomised (1:1) to (a) weight loss programme for a total of ~8 months (intervention) or (b) usual care; i.e., nurse-based consultation and supporting written material (control). All participants will undergo a baseline visit (prior to randomisation) and a follow-up visit at ~8 months. Both study visits will include a physical performance test (PPT), AF symptom assessment using the AFSS score, anthropometric measurements, quality of life assessment, Patient Health-Resource Use Questionnaire (PRUQ), MR scan, and blood sample collection. Additionally, prolonged ECG monitoring, and patient reported outcome measures (PROMs) will also be acquired at the 8-month visit. Finally, at approximately 4 months patients will be asked to complete interim questionnaires (including PRUQ, PROMs, Quality of Life) by post/telephone.
In the LOSE-AF trial, the intervention is at very low risk of adverse events and no Trial Steering Committee or Clinical Trial Authorization is required. The study will be coordinated by the Trial Management Committee (TMC), consisting of at least one core study investigator (a medically qualified clinician), and the research nurse. The TMC will be responsible for the day-to-day management of the trial and will meet regularly.
Inclusion Criteria:
Exclusion Criteria: